Elisabeth Eppard1, Michael Wuttke1, Philipp L Nicodemus1, Frank Rösch2. 1. Institute of Nuclear Chemistry, Johannes Gutenberg-University, Mainz, Germany. 2. Institute of Nuclear Chemistry, Johannes Gutenberg-University, Mainz, Germany frank.roesch@uni-mainz.de.
Abstract
UNLABELLED: Post-processing by means of a cation-exchanger-based protocol is an efficient strategy for purification and concentration of generator-derived (68)Ga. It ensures the removal of (68)Ge before (68)Ga-radiopharmaceutical preparation and high labeling yields of (68)Ga-labeled radiopharmaceuticals for routine medical application. METHODS: In an effort to overcome the problem associated with acetone in the currently applied method, we have investigated the feasibility of replacing it with ethanol. The purification of (68)Ga from coeluted metallic impurities ((68)Ge(4+), Fe(3+), Zn(2+), and Ti(4+)) on various cation-exchange columns has been investigated with a variety of post-processing solutions. As a proof of principle, the post-processed (68)Ga was used to radiolabel DOTATOC in combination with high-purity water and various buffer solutions. RESULTS: An effective protocol for the processing of generator-produced (68)Ga on the basis of cation-exchange chromatography using EtOH/HCl medium has been developed. Up to 95% of the initially eluted (68)Ga activity can be collected in a 1-mL fraction of 90% EtOH/0.9N HCl after removal of (68)Ge-breakthrough in a washing step. The post-processed eluate has been used to radiolabel DOTATOC in yields of approximately 97% ± 0.25% at 80°C in 5 min. CONCLUSION: The described novel protocol improves the radiolabeling efficiency and efficacy of DOTATOC, providing yields of greater than 99% (decay-corrected). As a result, further purification to separate the desired product from uncomplexed (68)Ga is not necessary. The developed post-processing and labeling protocols permit reliable and high-yield preparation of injectable (68)Ga-DOTATOC (or other (68)Ga-labeled radiopharmaceuticals) that are suitable for routine application. It is possible to incorporate this protocol into existing automated modules.
UNLABELLED: Post-processing by means of a cation-exchanger-based protocol is an efficient strategy for purification and concentration of generator-derived (68)Ga. It ensures the removal of (68)Ge before (68)Ga-radiopharmaceutical preparation and high labeling yields of (68)Ga-labeled radiopharmaceuticals for routine medical application. METHODS: In an effort to overcome the problem associated with acetone in the currently applied method, we have investigated the feasibility of replacing it with ethanol. The purification of (68)Ga from coeluted metallic impurities ((68)Ge(4+), Fe(3+), Zn(2+), and Ti(4+)) on various cation-exchange columns has been investigated with a variety of post-processing solutions. As a proof of principle, the post-processed (68)Ga was used to radiolabel DOTATOC in combination with high-purity water and various buffer solutions. RESULTS: An effective protocol for the processing of generator-produced (68)Ga on the basis of cation-exchange chromatography using EtOH/HCl medium has been developed. Up to 95% of the initially eluted (68)Ga activity can be collected in a 1-mL fraction of 90% EtOH/0.9N HCl after removal of (68)Ge-breakthrough in a washing step. The post-processed eluate has been used to radiolabel DOTATOC in yields of approximately 97% ± 0.25% at 80°C in 5 min. CONCLUSION: The described novel protocol improves the radiolabeling efficiency and efficacy of DOTATOC, providing yields of greater than 99% (decay-corrected). As a result, further purification to separate the desired product from uncomplexed (68)Ga is not necessary. The developed post-processing and labeling protocols permit reliable and high-yield preparation of injectable (68)Ga-DOTATOC (or other (68)Ga-labeled radiopharmaceuticals) that are suitable for routine application. It is possible to incorporate this protocol into existing automated modules.
Authors: Euy Sung Moon; Sanjana Ballal; Madhav Prasad Yadav; Chandrasekhar Bal; Yentl Van Rymenant; Sarah Stephan; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Roesch Journal: Am J Nucl Med Mol Imaging Date: 2021-12-15
Authors: Dániel Szücs; Tibor Csupász; Judit P Szabó; Adrienn Kis; Barbara Gyuricza; Viktória Arató; Viktória Forgács; Adrienn Vágner; Gábor Nagy; Ildikó Garai; Dezső Szikra; Imre Tóth; György Trencsényi; Gyula Tircsó; Anikó Fekete Journal: Pharmaceuticals (Basel) Date: 2022-05-26
Authors: Alexandra I Fonseca; Vítor H Alves; Sérgio J C do Carmo; Magda Silva; Ivanna Hrynchak; Francisco Alves; Amílcar Falcão; Antero J Abrunhosa Journal: Pharmaceuticals (Basel) Date: 2022-06-07
Authors: Maria Iris Tsionou; Caroline E Knapp; Calum A Foley; Catherine R Munteanu; Andrew Cakebread; Cinzia Imberti; Thomas R Eykyn; Jennifer D Young; Brett M Paterson; Philip J Blower; Michelle T Ma Journal: RSC Adv Date: 2017-10-25 Impact factor: 3.361
Authors: Dirk Mueller; Wouter A P Breeman; Ingo Klette; Michael Gottschaldt; Andreas Odparlik; Manfred Baehre; Izabela Tworowska; Michael K Schultz Journal: Nat Protoc Date: 2016-05-12 Impact factor: 13.491
Authors: Euy Sung Moon; Yentl Van Rymenant; Sandeep Battan; Joni De Loose; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Rösch Journal: Molecules Date: 2021-06-08 Impact factor: 4.411
Authors: Michelle T Ma; Carleen Cullinane; Kelly Waldeck; Peter Roselt; Rodney J Hicks; Philip J Blower Journal: EJNMMI Res Date: 2015-10-09 Impact factor: 3.138
Authors: Florian C Gaertner; Khalil Halabi; Hojjat Ahmadzadehfar; Stefan Kürpig; Elisabeth Eppard; Charalambos Kotsikopoulos; Nikolaos Liakos; Ralph A Bundschuh; Holger Strunk; Markus Essler Journal: Oncotarget Date: 2017-07-06
Authors: Elisabeth Eppard; Ana de la Fuente; Nicole Mohr; Mareli Allmeroth; Rudolf Zentel; Matthias Miederer; Stefanie Pektor; Frank Rösch Journal: EJNMMI Res Date: 2018-02-27 Impact factor: 3.138